Philippe Saas
  • E-mail :[email]
  • Phone : 0381615615
  • Location : Besançon, France
Last update 2012-03-06 14:51:03.441

Philippe Saas PhD in Immunotoxicology

Course and current status

Current position:

- Senior Scientist (since 1999) and Director (since January 2012), INSERM unit (UMR1098, ex-645) entitled "Host-Graft-tumor Interactions and Cell and Gene Therapy" - Head of a research team called "Tolerance, Inflammation in Transplantation" (since 2008) 

- Professor, University of Franche-Comté, Immunology and Cell Therapy, Faculty of Medicine and Pharmacy, Besançon, France (since 2005)

- Head of Biomonitoring laboratory (laboratory medicine), EFS B/FC, Besançon, France (since 2005) web site address:


2000: Research Habilitation Degree, University of Franche-Comté, Besançon, France

1998: Post-doctoral fellowship, Laboratory of Tumor Immunology, Division of Oncology, University Hospital, Geneva, Switzerland

1997: PhD, Immunotoxicology, University of Metz, France

Scientific summary

The research unit headed by Prof. Saas mainly focuses on i) the evaluation of donor-recipient interactions in the setting of kidney or hematopoietic cell (HC) transplantation, and ii) the development of cell-based and ex vivo gene therapy approaches to modulate donor-recipient interactions and thus increase overall transplantation efficacy. He studies the interactions between the immune system and apoptotic cells in order to propose apoptotic cell infusion as an alternative cell-based therapy approaches. This part of this work is performed in collaboration with Dr Sylvain Perruche.

In 2005 Prof. Saas founded the Biomonitoring Platform, a joint laboratory of the French Blood Agency and Besançon University Hospital dedicated to the biological follow-up of patients included in biotherapy studies (i.e., cell therapy including transfusion or monoclonal antibody) or receiving organ transplantation. In collaboration with Prof D. Ducloux, Prof. Saas works on the identification of biomarkers predictive of transplantation-associated complications including cancers and accelerated atherosclerosis.

Image d’exemple